CLINICAL TRIALS PROFILE FOR MESCALINE

Clinical Trials for Mescaline

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00465595 ↗	Psychopharmacology of Psilocybin in Cancer Patients	Completed	Heffter Research Institute	Phase 2	This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices.
NCT00465595 ↗	Psychopharmacology of Psilocybin in Cancer Patients	Completed	Johns Hopkins University	Phase 2	This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices.
NCT00465595 ↗	Psychopharmacology of Psilocybin in Cancer Patients	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 2	This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices.
NCT04227756 ↗	Comparative Acute Effects of LSD, Psilocybin and Mescaline	Recruiting	University Hospital, Basel, Switzerland	Phase 1	LSD, psilocybin and mescaline are widely used for recreational and ethnomedical purposes. All three substances are thought to induce prototypical psychedelic effects primarily via stimulation of the 5-HT2A receptor. However, there are differences in the substances' molecular structures and receptor activation profiles which may induce differential subjective effects. To date, there are no modern studies comparing LSD, psilocybin and mescaline directly within the same clinical study and research subjects using validated psychometric tools. Therefore, the LPM-Study compares the acute effects of LSD, psilocybin, mescaline and placebo in a double-blind, placebo-controlled, 4-period cross-over design with four treatment conditions: 1) 100 μg LSD, 2) 20 mg psilocybin, 3) 300 or 500 mg mescaline, and 4) placebo.
NCT04849013 ↗	Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness	Recruiting	University Hospital, Basel, Switzerland	Phase 1	Mescaline (the active substance in Peyote and San Pedro cacti) is a classic and long known serotonergic psychedelic substance (hallucinogen) that is widely used for recreational, spiritual, and/or ethno medical purposes. Despite its long history, modern data on the acute effects of mescaline on human is lacking. Mescaline produces prototypical psychedelic effects, similar as lysergic acid diethylamide (LSD) and psilocybin. The serotonin 2A (5-HT2A) receptor is thought to primarily mediate acute alterations of consciousness induced by LSD and psilocybin. However, the contributory role of the 5-HT2A receptor in mescaline-induced alterations of consciousness is unclear. Using 5-HT2A receptor antagonist ketanserin, the psychedelic experience induced by LSD and psilocybin can be attenuated and shortened. The present study therefore explores the role the 5-HT2A receptor in mescaline-induced altered states of consciousness using escalating doses of mescaline and the 5-HT2A receptor blocker ketanserin administered before a high dose of mescaline. Objective: The present MDR-study will characterize the subjective effects of different doses of mescaline using modern psychometric instruments and examine the contribution of the 5-HT2A receptor in the mescaline-induced alterations of consciousness. Design: Double-blind, placebo-controlled, 6-period cross-over design with six treatment conditions. 1) Placebo (Pla + Pla), 2) 100 mg mescaline (Pla + 100mg mescaline), 3) 200 mg mescaline (Pla + 200mg mescaline), 4) 400 mg mescaline (Pla + 400mg mescaline), 5) 800 mg mescaline (Pla + 800mg mescaline), and 6) 40mg ketanserin and 800mg mescaline (Ket + 800mg mescaline). Participants: 16 healthy participants aged ≥ 25 and ≤ 65 years (8 female, 8 male)
NCT05523401 ↗	Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects	Not yet recruiting	University Hospital, Basel, Switzerland	Phase 1	2-bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive substance with reportedly similar acute effects to both the prototypical empathogen 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and the classic psychedelic substance psilocybin (contained in "magic, hallucinogenic mushrooms"). Pharmacologically, MDMA mainly releases serotonin (5-HT) via the serotonin transporter (SERT) and psilocybin mainly acts as direct agonist at 5-HT2A receptors. 2C-B interacts with both the 5-HT2A receptor and SERT which is in line with its reported mixed effects profile. However, scientific studies are lacking. There is an increased interest in psychiatric research on the therapeutic properties of MDMA and psilocybin and also on mixed empathogenic-psychedelic substances.
NCT06884514 ↗	Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects	RECRUITING	University Hospital, Basel, Switzerland	PHASE1	The acute subjective effects of serotonin (5-HT)2A receptor stimulation with psilocybin in humans are mostly positive. However, negative effects such as anxiety, paranoid thinking, or loss of trust towards other people are common effects, depending on the dose administered, the personality traits of the person consuming it (set), or the environment in which psilocybin is taken (setting). Negative psychedelic effects may cause acute distress to the subject and acute anxiety has been linked to less favorable long-term outcomes in patients experimentally treated with psilocybin or similar substances for the treatment of depression. The 5-HT and oxytocin releaser 3,4-methylenedioxymethamphetamine (MDMA) reliably induces positive mood, euphoria, comfort, empathy, and feelings of trust. If administered in combination with psilocybin, MDMA may increase positive subjective drug effects including positive mood, empathy, and trust and reduce negative emotions and anxiety associated with psilocybin and overall produce a more positive over negative experience. The present study will assess subjective and autonomic effects of psilocybin alone and in combination with MDMA.

Clinical Trial Conditions for Mescaline

Condition Name

Condition Name
Intervention	Trials
Healthy	4
Anxiety	1
Cancer	1
Depressive Symptoms	1

Condition MeSH

Condition MeSH
Intervention	Trials
Depression	1

Clinical Trial Locations for Mescaline

Trials by Country

Trials by Country
Location	Trials
Switzerland	3
United States	1

Trials by US State

Trials by US State
Location	Trials
Maryland	1

Clinical Trial Progress for Mescaline

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
PHASE1	1
Phase 2	1
Phase 1	3

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	3
Completed	1
Not yet recruiting	1

Clinical Trial Sponsors for Mescaline

Sponsor Name

Sponsor Name
Sponsor	Trials
University Hospital, Basel, Switzerland	4
Heffter Research Institute	1
Johns Hopkins University	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Other	7